#AAPM2024 is just around the corner, and we’d love to know what you think the hottest #medphys topics will be in Los Angeles.
Innehållet är inte tillgängligt här
Få tillgång till det här innehållet och mycket mer i LinkedIns app
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in 120 countries and listed on Nasdaq Stockholm. Visit elekta.com to learn more.
Extern länk för Elekta
Alberto Bossi, MD, underscores brachytherapy's dual advantages for #prostatecancer patients. By enhancing local disease control and offering a patient-friendly side effect profile—especially with HDR #brachytherapy—it emerges as a pivotal treatment choice. His insights illuminate the transformative potential of this approach in prostate cancer care. Find it here ➡️ https://bit.ly/3SicX9B #MedicalAdvancements #CancerCare
Leksell #GammaKnife SRS or Vascular Decompression for #TrigeminalNeuralgia?💡 For Dr. Balossier, these treatment options are complementary and which to choose depends on the patient. Being able to offer both helps her personalize the treatment journey and leads to pain elimination in around 90% of her radiosurgery cases. Read the case study ➡️ https://bit.ly/4eFZulg
Attending #AAPM2024? Join Elekta at Cabra where we'll announce Elekta ONE | Planning. Discover how our innovative solutions are making a difference and connect with like-minded #medphys professionals who share your commitment to improving outcomes ➡️ https://bit.ly/3zBlWfa
Revolutionary MR-Linac treatment at University of Tübingen offers rectal cancer patients a non-surgical option with high quality of life. Prof. Dr. Cihan Gani shares how MR-guided therapy could help patients avoid a colostomy. Want to learn more about MR-guided radiation therapy for rectal cancer? Click here ➡️ https://bit.ly/3S0dk8j #MRgRT #radiotherapy
Our Annual Report for 2023/24 is available and may be downloaded here ➡️ https://bit.ly/3zwuWlU. The report also contains Elekta's Sustainability Notes, the Corporate Governance Report and the Remuneration Report.
This week, we had the honor of accompanying Datuk Seri Zambry Abd Kadir, the Malaysian Minister of Higher Education, on a visit to Institut Perubatan dan Pergigian Termaju, Universiti Sains Malaysia where he learned about their radiotherapy services. During the visit, Elekta's Head of Marketing for Asia Pacific & Japan, Yohei Watanabe, recognized the hospital as a leading BrachyAcademy site and Paul Lee, Head of the Brachytherapy Business Line for Asia Pacific & Japan, presented a research grant to explore the potential of oral tongue brachytherapy. We'd like to thank Dr. Yusri Musa, Lecturer and Otorhinolaryngologist/Head & Neck Cancer Specialist and Assoc. Prof. Gokula Appalanaido, Head of Radiation Oncology, for the visit and their clinical partnership.
To encourage work-life harmony and well-being among employees, Elekta kicked off a company-wide initiative, the Pink Ribbon Challenge, in January. Supporting the Elekta Foundation, the challenge has had employees lacing up their running shoes and embracing the spirit of camaraderie all over the globe. Here’s a glimpse at some of the fun we’ve had clocking up miles and kilometers, all leading up to the race in September. #LifeatElekta
For MR-Linac users who plan to treat pancreatic tumors, MR-guided SBRT has been established as a novel and promising therapy – with early outcomes demonstrating prescribed doses up to 50 Gy in five fractions can safely be delivered while maintaining low acute toxicity rates. Read more in this research article ➡️ https://bit.ly/3VKFAht #MRgRT